Beneficial effects of pharmacotherapy on weight loss, depressive symptoms, and eating patterns in obese binge eaters and non-binge eaters

Obesity Research

Volumn 7, Issue 5, 1999, Pages 469-476

  Alger, Sharon A ^a   Malone, Margaret ^a   Cerulli, Jennifer ^a   Fein, Steven ^a   Howard, Lyn ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Binge eaters; Non binge eaters

Indexed keywords

ANOREXIGENIC AGENT; FENFLURAMINE; PHENTERMINE;

ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; DEPRESSION; DRUG EFFECT; EATING; EATING DISORDER; ECHOGRAPHY; FEMALE; HUMAN; MALE; MIDDLE AGED; OBESITY; PSYCHOLOGICAL ASPECT; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

ADULT; APPETITE DEPRESSANTS; DEPRESSION; EATING; EATING DISORDERS; FEMALE; FENFLURAMINE; HEART VALVE DISEASES; HUMANS; MALE; MIDDLE AGED; OBESITY; PHENTERMINE; WEIGHT LOSS;

EID: 0033193392     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1550-8528.1999.tb00435.x     Document Type: Article

References (10)

1. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes. 1998;22:39-47.
2. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med. 1993;119:655-60.
3. Wolf AM. What is the economic case for treating obesity? Obes Res. 1998;6:2(s)-7.
4. Meisler JG, St. Jeror S. (eds). American health foundation roundtable on healthy weight. Am J Clin Nutr. 1996;63:3(s): 409(s)-11.
5. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years. Am J Epidemiol. 1995;141(12):1128-41.
6. National Institutes of Health. Technology assessment conference panel. Methods for voluntary weight loss and control. Ann Intern Med. 1993;119:764-70.
7. Connolly HM, Crary JL, McGoon MD, et al. Valvular disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581-8.
8. Rippe JM. The case for medical management of obesity: a call for increased physician involvement. Obes Res. 1998;6 (1s): 23(s)-33.
9. Hanotin T, Thomas F, Leutenegger E, Drouin P. Efficacy and tolerability of sibutramine in obese patients: a dose ranging study. Int J Obes. 1998;22:32-8.
10. McNeely W, Benfield P. Orlistat. Drugs. 1998;56(2):241-9.